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Abstract 
BACKGROUND: The second leading cause of cancer-related death in women is breast cancer. Xenobiotic 
Metabolizing Enzymes (XMEs) contribute to the detoxification of numerous cancer therapy-induced products. In 
the metabolism of xenobiotic, cytochrome P450s or monooxygenases perform an important function by catalysing 
the hydroxylation reaction. In this study, the susceptibility and genetic polymorphisms of CYP450 isoenzymes was 
investigated that may have an etiological role in breast cancer.  
AIM: The main purpose of this study was to evaluate the association of CYP1A1 (rs4646421), CYP1B1 
(rs1056836), CYP2C8 (rs1058930), and CYP19A1 (rs749292) polymorphisms with the risk of breast cancer in 
Mazandaran province. 
MATERIAL AND METHODS: This cross-sectional case-control study were recruited 72 patients and 51 healthy 
individuals and was performed between March 2018 to May 2018 in the Oncology Department at Imam Hospital 
in Sari city, Iran. Peripheral blood samples were collected in EDTA tube, and DNA extraction was performed using 
the salting-out method and WizPrep extraction kits. Breast cancer patients with known clinicopathological 
characters and healthy women as control group were genotyped for genes polymorphisms by PCR-RFLP 
technique, using restriction enzymes. Chi-square, Fisher exact test and Logistic regression model, were applied 
for statistical analysis. 
RESULTS: The results of the experiments showed that there was a significant relationship between two groups 
and the age of the patients is significantly higher than the control group (p = 0.044). According to the chi-square 
and Fisher exact test, education, pregnancy, menopause status and oppose were significant between the two 
groups. Based on using a logistic regression model in two normalized and age-adjusted models to finding 
relationship between the genotypes of each gene and breast cancer risk, it was determined that in the CYP2C8 
genotype, those who have the CG allele have a 7.74 degree increased risk of breast cancer (CI = 95% 0.95-62.5) 
and in the CYP19A1 gene, individuals with GA genotype, increased risk of breast cancer (CI = %95 1.52-27.21), 
about the CYP1B1 gene, people with two genotypes of CG + GG had higher risk of breast cancer (CI = %95 1.19-
5.71) and allele G has decreased risk of breast cancer in this gene (P = 0.0271), also allele G in CYP2C8 gene 
had the protective effect (P = 0.02). In the age-adjusted model, for the CYP2C8 gene, GG genotype increased 
risk of breast cancer (CI = %95 1.11-75.84) as well as, the CG + GG genotype in CYP1B1 gene (CI = %95 1.31-
6.57). 
CONCLUSION: Our results confirm the association between CYP2C8 (rs1058930), CYP19A1 (rs749292) and 
CYP1B1 (rs1056836) gene polymorphisms and increased risk of breast cancer in women in Mazandaran 
province. 
 
 
Introduction 
 
Breast cancer is the most frequent 
malignancy in women in all races and a growing 
number in advanced and underdevelopment countries 
in Asia. According to a report of Iran’s Ministry of 
Health and Medical Education, breast cancer is the 
most common primary cancer in Iranian women [1]. 
Today, this disease accounts for about one-third of all 
cancers in women, and it represents the second 
leading cause of cancer death among women (15% of 
cancer deaths) after lung cancer. According to WHO 
statistics, one in every 8 to 10 women have breast 
cancer [2]. According to the latest statistics from the 
Iranian Cancer Research Center, breast cancer cases 
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in Iran are one decade younger than their western 
counterparts [3]. About 8500 new cases of breast 
cancer are reported annually in the country that 1400 
cases are reported died from breast cancer; it is also 
estimated in 2014, about 40,000 people were living 
with this disease [4]. 
Breast cancer disease is defined as 
uncontrolled growth of cells in breast tissue, which is 
caused by abnormal growth in the glands which have 
role of producing milk (lobules) or in the ducts that 
connect lobules to the nipple duct [5] and also is a 
heterogeneous disease [6] that is caused by 
environmental and genetic factors [7]. The genetic 
damage caused by endogenous and exogenous 
metabolites could be a cause of breast cancer. 
Clinical and epidemiological studies have 
demonstrated that estrogen and progesterone play a 
significant role in the growth and differentiation of 
normal tissue in the breast [8]. 
The aetiology of breast cancer is complex and 
still poorly understood. A small proportion of breast 
cancer cases can be attributed purely to genetic 
reasons whereas risk factors such as age, 
reproductive events (menarche, menopause, 
pregnancy, breastfeeding), estrogens, exogenous 
hormones (hormone replacement therapy and oral 
contraceptives), lifestyle and exposure to 
environmental carcinogens (pollution, alcohol, diet, 
obesity), ionizing radiation, chemopreventive agents, 
as well as genetic factors, breast cancer susceptibility 
genes high penetrance genes (BRCA1, BRCA2, 
PTEN) and low penetrance genes (CYP450, GSH, 
UGTA) that encodexenobiotic metabolizing enzymes 
in phase І and ІІ of metabolism [9]. As mentioned 
above, one of the main risk factors for breast cancer is 
estrogen, and there are two forms of estrogen in our 
body: endogenous estrogen that biosynthesises from 
cholesterol in the body, then undergoes metabolic 
processes and exogenous form (hormonal drugs, 
etc.). The main effect of estrogens is stimulating of the 
breast cells and increases the chance of errors during 
multiple DNA divisions and the possibility of mutations 
[10]. Also, it has been identified that Xeno-estrogens, 
which include pesticides, paints, contaminants, 
plastics and food preservatives, would have similar 
effects with estrogen, and contributed to the causes of 
breast cancer. They have endocrine disruption effects 
[11]. 
Many carcinogenic compounds are oxidized 
by phase I enzymes, represented by cytochrome 
P450 family, into reactive metabolites that are 
detoxified by phase II enzymes. GSTs are a family of 
Phase II detoxification enzymes that catalyse the 
conjugation of glutathione (GSH) to a wide variety of 
xenobiotic. This detoxification ability plays an 
important role in cellular protection from 
environmental and oxidative stress. Hence, the toxic 
effects of exposure, absorption and detoxification of 
carcinogens depend on a delicate balance between 
the phase I and phase II enzymes [12], [13]. The 
cytochrome P450 and GSTs, UGTA and etc.that 
phase II enzymes increase its solubility in such a way 
as to facilitate its excretion and detoxification. These 
genes involved in the metabolism of these toxins 
(cytochrome p450), and also contribute to the 
pathway of biosynthesis and estrogen metabolism, 
and also contribute to the progression of breast 
cancer Polymorphisms in both phase I and phase II 
enzyme genes may result in alteration of their 
expression, function and activity. These genes are 
regulated at the transcriptional level, and their 
expression is influenced by genetic factors, 
polymorphism in the structural and regulatory gene 
and by environmental factors [14], [15]. 
Polymorphisms and expression pattern of these 
genes are believed to be key factors in determining 
cancer susceptibility to toxic or environmental 
chemicals [16]. Polymorphisms are including single 
nucleotide polymorphisms (SNPs). The most common 
form of human genetic differences is single Nucleoid 
Polymorphisms (SNPs) which may play an important 
role in individual allergies. Single-nucleotide 
polymorphism is a change in only one open DNA. 
These single-nucleotide variations cause different 
phenotypes, predisposing to or susceptibility to certain 
diseases. 
SNPs in genes involved in xenobiotic 
metabolism and estrogen biosynthesis and 
metabolism might affect circulating estrogen levels 
and modulate the individual susceptibility to 
environmental carcinogens about developing breast 
cancer [10]. Candidate genes for this study are low-
penetrance breast carcinoma susceptibility include 
those encoding for Xenobiotic Metabolizing Enzymes 
(XMEs) involved in carcinogen metabolism and 
detoxification [17]. These XMEs can be divided into 
phase I (Cytochrome P450 family) and phase II (GST, 
UGTA, etc.) enzymes that metabolically activate 
potentially carcinogenic forms. In this study, 
polymorphisms of phase I enzymes CYP1A1 
(rs4646421C/T), CYP2C8 (rs1058930C/G), CYP1B1 
(rs1056836 C/G) and CYP19A1 (rs749292A/G) in 
breast cancer patients who referred to Mazandaran 
province clinics, during March 2018 to May 2018 were 
investigated. DNA extracted from peripheral blood 
leukocytes of patients with breast cancer and healthy 
patients. Identifying the genetic polymorphisms of 
breast cancer patients, in order to recognizing the 
mechanism of the disease is effective on diagnosis 
and screening patients who are prone to the disease 
and, therefore, preventing them. So, position, 
structure and function of studied genes were briefly 
explained, then polymorphisms of them were studied. 
CYP1A1 is one of the “phase I” enzymes 
located on chromosome 15q22-q24 and is a 5987-bp 
long gene. It has 7 exons and 6 introns that encodes 
for a 512 amino acid protein. This is one of the major 
components of the detoxification pathway that is 
highly expressed in non-hepatic cells, such as breast 
tissue [18]. It is a polymorphic gene involved in the 
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metabolism of steroids and several potentially 
genotoxic chemicals. In estrogen metabolism, it plays 
a main role in producing of2-hydroxy estrogens. Four 
single nucleotide polymorphisms (SNP) were 
identified inCYP1A1 gene including M1, T/C transition 
at nucleotide 3801; M2, A/G transition at position 2455 
resulting in change of Ile to Val at codon 462; M3T/C 
transition at nucleotide 3205; and M4 C/A transition at 
position 2453 resulting in change of Thr to Asn at 
codon 461. The M1 polymorphism at 3’-flanking 
region (T3801C) was verified to be associated with 
increased activation of carcinogens [19], [20]. 
CYP1B1 is located on chromosome 2 at position 
2p22.2. The gene is 42930-fold-wide and 60846 
Molecular weight. It has 3 exons and 2 introns and 
was considered as the key enzyme of P450, which is 
exogenous in metabolism and endogenous substrate. 
CYP1B1 plays the main role in the 
metabolism of androgens and estrogen substrates. 
CYP1B1 can catalyse 4-hydroxyl-estrogens, which is 
a key reaction to hormonal carcinogenesis. CYP1B1, 
5 different SNPs have been identified that can play a 
vital role in replacing amino acids A119S, R48G, 
L432V, A443G and N453S. Val432Leu- polymorphism 
has recently been identified as the most influential 
agent on the catalytic properties of CYP1B1 and will 
also affect the function of 4-hydroxy in the Val32 
allele, which indicates a 3-fold increase in activity 
relative to the Leu432 allele, for the specific CYP1B1 
gene rs 163077, 163086 and 162556 who are 
involved with invasive breast cancer [21], [22]. 
CYP19A1 is located on chromosome 15, q21.2, 
consisting of 18 exons and 17 introns, and has a 
molecular weight of 57883 Da. The enzyme is 
stagnant, which plays an important role in 
biosynthesis and the final stages of estrogen 
biosynthesis. The aromatase is coded by the 
CYP19A1 gene, a key estrogen biosynthesis enzyme 
and play a vital role in the development of breast 
cancer. The main effect of this enzyme is in the 
catalysing of the final stage of estrogen biosynthesis 
that converts androstenedione and testosterone into 
estrogen and estradiol. The direct effect of aromatase 
on cytotoxicity in the breast is completely reported 
[23]. A high level of aromatase expression has been 
reported in breast tumours, which is also visible in the 
normal breast. CYP2C8 is located on chromosome 10 
at position 10q23.33 consisting of 10 exons and 9 
introns. This gene has 55825 Da molecular weight. 
CYP2C8 is one of the first human cytochromes and 
plays an important role in drug metabolism in 
cytochrome P450, which can also be used in 
response to chemotherapy and survival chances. 
Patients with breast cancer are more closely related to 
the metabolism of CYP2C8 * 2 and CYP2C8 * 3 [24]. 
 
 
 
 
Material and Methods 
 
Subjects 
A total of 123 unrelated subjects (51 controls 
and 72 patients), living in Mazandaran province were 
enrolled in this study. The cases were all new incident 
breast cancer patients histologically diagnosed at the 
Oncology Department of Cancer Research Center at 
Imam Hospital in Sari city in Iran, during the period of 
March 2018 to May 2018. Controls were randomly 
selected from healthy women who visited patients 
admitted to the same hospitals and were healthy 
blood donors having no evidence of any personal or 
family history of cancer, or other illnesses patients’ 
age ranged from 20 to 75 years. A detailed description 
of the clinical-pathological characteristics of this study 
was summarized in (Table1). Control subjects having 
years ranging from 23 to 66 years. Informed consent 
was obtained from all participants, and a structured 
questionnaire was administered by trained 
interviewers to collect information on demographic 
and anthropometric data, reproductive and medical 
history, residential history, and occupation as well, 
lifestyle, exposure parameters were reported in Table 
1. Tobacco smoking and alcohol consumption also 
were asked from the subject, but there was no case. 
To investigate whether certain genotypes are a 
susceptible marker, 5 ml peripheral blood was 
collected in the EDTA tube from both patients and 
control group and stored at -20°C.  
Table 1: Comparison of cases and controls by selected 
demographic factors and major risk factors for breast cancer 
 
Clinic pathological Variables  
 
Cases Controls P value 
Age (mean ± SD) 48.08 ± 10.3 43.69 ± 13.5 0.044* 
Age at menarche (mean ± SD) 1.2 ± 13.15 1.2 ± 13.31 0.485 
Age at menopause (mean ± SD) 4.4 ± 21.52 5.0 ± 22.55 0.274 
Age at 1 St pregnancy (mean ± SD) 4.4 ± 49.53 8.7 ± 47.13 0.21 
Age < 45, n (%) 31 (43%.1) 29 (56%.9) 
0.13 
Age > 45, n (%) 41 (56%.9) 22 (43%.1) 
Pregnancy, n (%)    
NO 6 (8%.3) - 
0.036* 
YES 66 (91%.7) - 
Oral contraceptive use, n (%)     
NO 38 (52%.8) 36 (70%.6) 
0.047* 
YES 34 (47%.2) 15 (29%.4) 
Menopause Status, n (%)    
Premenopausal 29 (40%.3) 30 (58%.8) 
0.043* 
Past menopausal 43 (59%.7) 21 (41%.2) 
Body mass index, n (mean±SD kg/m
2
)    
BMI < 20 kg/m2 3 (4%.2) 3 (5%.9)  
20 ≤ BMI < 25 19 (26%.4) 14 (27%.5) 0.9 
BMI ≥ 25 50 (69%.4) 34 (66%.6)  
Family history of breast cancer in first-
degree relatives n (%) 
   
No 53 (73%.6) - < 001* 
Yes 19 (26%.4) -  
Education, n (%)    
≤ 12 years 41 (56%.9) 12 (23%.5) 
< 001* 
> 12 years 31 (43%.1) 39 (76%.5) 
Occupational exposure to pesticides 
(Agriculturist), n (%) 
   
NO 52 (72%.2) - 
< 001* 
YES 20 (27%.8) - 
Grade, n (%)    
I 13 (18%.1) -  
II 47 (65%.3) - < 001* 
III 12 (16%.7) -  
Stage, n (%)    
I 5 (6%.9) - < 001* 
II 42 (58%.3) -  
III 18 (25%.0) -  
IV 7 (9%.7) -  
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DNA extraction 
Blood samples were collected in EDTA-
containing tubes, and genomic DNA was isolated from 
buffy coats using a WizPrep DNA blood kit and 
salting-out method [25]. In the method by using 
extraction kit, in the presence of strong anionic 
detergents, the white blood cells are lysed, then 
proteins are removed with dehydration and 
prophylaxis. Briefly, 200 µl of blood were mixed with 
20 µl protein kinase K, then 200 µl GB buffer was 
added then the mixture was incubated (10 min 56°C), 
200 µl EtOH %100 was added. Then, washing buffer 
1 and 2 was added. In the final step, 50 µl Elution 
Buffer was added. Precipitated proteins were removed 
by centrifugation. The DNA in the supernatant fluid 
was precipitated with ethanol. In every step, we 
centrifuged the mixture based on the protocol of the 
kit. The DNA pellet was dissolved in 400 μl of sterile 
distilled water. After extraction, the quality and 
quantity of the extracted DNA were measured by the 
spectrophotometer. Then, DNA samples were stored 
at -20°C, and its purity was checked through agarose 
following the protocol of the manufacturer. SNPs were 
genotyped. 
 
Genotyping 
Polymorphic sites of genes were genotyped 
by Polymerase Chain Reaction-Restriction Fragment 
Length Polymorphism (PCR-RFLP) assay. 
Amplification was performed using a specific primer. 
Pair of Primers were designed using Gene Runner 
software. The sequence of primers is listed in (Table 
2) reaction contain. 25 μl Polymerase Chain Reaction 
(PCR) containing 2 μl genomic DNA (100 ng/μl), 12.5 
μl Master mix PCR, and 1 μl (10 picomols) of each 
primer which ultimately reached 25 μl with distilled 
water. The PCR reaction program was set for each 
gen. Then the product of the enzyme was digested. 
Digestion was electrophoresed on 2% agarose gel 
and photos were taken by Gel Doc [26]. 
Table 2: Primers and restriction enzymes used for 
polymorphism genotyping 
Genes SNP Polymorphisms Primers 
Restriction 
enzymes 
CYP1A1 rs 4646421 
Intron/splice 
mutation (m1) 
3'uR T→C 
(T56392) (+303C>T) 
Forward 
CCATTTATTCTCTG: 
CTCTCTGGTA 
Reverse 
CCCACCACACTTAGGA
AAATCA 
RsaI 
CYP1B1 rs1056836 
 
CYP1B1*3 
Exon3/missensc 
C251G (Val432 Leu) 
Forward 
CTGTGGTTTTTGTCAA
CAAGTGGTC 
Reverse 
TGAGCCAGGATGGAG
ATGAAGAGA 
BsrI 
CYP19A11 rs749292 Intron / Exon1 
Forward 
CCAAGGTCCCACAGCT
AATTAGTGA 
Reverse 
TAAAAGGGCAAGAGCA
GAGATGAGC 
Taql 
CYP2C8 rs1058936 
CYP2C8*4 
Exon5/missense 
C792G 
(ILe 264 Met) 
Forward 
AATCAGGGCTTGGTGT
AAGATA 
Reverse 
CGATGAATCACAAAAT
GGACAAG 
Taql 
 
Polymorphisms analysis 
Previously reported primers and restricted 
enzymes in RFLP-PCR are listed in (Table 2). All PCR 
reactions were performed in an independent blinded 
duplicate manner, and for each polymorphism, some 
samples were confirmed by sequencing the PCR 
products. 
The polymorphic site of the CYP1A1 (rs 
4646421) (C—T intron) was determined by 
polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP). A 519 bp fragment 
containing C/T allele was amplified. Using forward and 
reverse primers that the specifications of primers and 
size of product and restriction enzymes of genes have 
been explained in the (Table 2). CYPP1B1 
(rs1056836) (C-Gval432leucin) also simultaneously 
revealed by Restriction Fragment Length 
Polymorphism (PCR-RFLP) PCR reaction was 
performed in a total volume of 50 μl containing 100 ng 
of genomic DNA, 200 μmol dNTPs, 2 mM MgCl2, 1 × 
Taq polymerase buffer, 100 pmol of CYP1A1 and 
CYP1B1 (primers and 1 U of Taq DNA polymerase). 
There action conditions used with the thermal cycler 
were as follows for CYP1A1: initial denaturation at 
95°C for 5 min, 32 cycles of denaturation at 95°C for 
30 sec, annealing at 62°C for 30 sec and extension at 
72°C for 30 sec and a final extension at 72°C for 10 
min for CYP1B1 annealing set at 66.5°C for 30 sec. 
To verify proper amplification conditions, 10 μl of PCR 
product were analysed on a 2% agarose gel and 
stained with ethidium bromide, the amplification of 
was revealed by the presence of bands. To detect 
CYP1A1 (C-T) and CYP1B1 (C-G) polymorphisms, 
amplified DNA was digested with 10 U of Fast Digest 
RsaI (37°C, 5 min) and BsrI (65°C, 16 h) restriction 
enzymes. In CYP1A1 the homozygote wild-type CC 
genotype produces two 183 and 36 bp fragments, 
homozygote mutated TT genotype results in single 
band of 183 bp length, and heterozygote TC genotype 
produces three fragments of 519, 183 and 336 bp 
fragments and in CYP1B1 homozygote wild-type CC 
genotype produce single band of 44 bp length, 
homozygote mutated GG genotype results from two 
44 and 171 bp fragments and heterozygote GC 
genotype produce three fragments of 215, 171, and  
44 bp fragments. 
To verify proper amplification conditions, 10 μl 
of PCR product were analysed on a 2% agarose gel 
and stained with ethidium bromide, the amplification of 
was revealed by the presence of bands. Homozygote 
wild-type CC genotype produce single band of 44 bp 
length, homozygote mutated GG genotype results 
from two 44 and 171 bp fragments and heterozygote 
GC genotype produces three fragments of 215, 
171and 44 bp fragments. Digestion conditions were 
performed according to the manufacturer's 
instructions and summarized for each gen in (Table 
3). 
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Digestion products were separated at the 
appropriate concentrations on a 2, 3 or 4% Low-
melting point agarose gel and stained with ethidium 
bromide. The splice-site mutation of CYP19A1 
(rs749292) (A-G intron) and CYP2C8*4 (rs1058930) 
(C-G exon5) was also analysed by PCR-RFLP. PCR 
amplification also was performed the same as the 
above genes. The cycling conditions for both of genes 
including one pre-treatment cycle denaturation at 
94°C for 5 min, 32 cycles of denaturation at 94°C for 
30 sec, followed by annealing at 66°C for 30 sec and 
elongation at 72°C for 25 sec and a final elongation at 
72°C for 10 min. Products were analysed by 
electrophoresis at 2% agarose gel and visualised by 
ethidium bromide staining. This amplified fragment 
was digested TaqI restriction enzyme at 65°C 
overnight and was analysed on 2% agarose gel. 
CYP19A1 when digested with TaqI the homozygote 
wild-type GG genotype results from two 144 and 214 
bp fragments, homozygote mutated AA genotype 
produce single band of 144 bp and heterozygote GA 
genotype produce three fragments of 358, 144 and 
214 bp fragments whereas Digestion of CYP2C8 
yielded band of 84 bp, and heterozygote GC genotype 
produces three fragments of 303, 84 and 219 bp 
fragments (Table 3). 
Table 3: Restriction enzymes conditions used for Genes 
polymorphism genotyping 
SNPS Restriction Enzymes 
Temperature and 
Incubation time 
Fragment size (bp) 
rs4646421 FastDigestRsaI (10 µ) 37ºC-5 min 519, 183 + 336 
rs1056836 BSrI (10 µ) 65ºC-1h16 215, 44 + 171 
rs749292 TaqI (10 µ) 65ºC-1h16 358, 144 + 214 
rs1058930 TaqI (10 µ) 65ºC-1h16 303, 84 + 219 
 
Statistical analysis 
The genotype and allele frequency of the 
genes were tested for both patient and control group 
using chi-square test, Fisher exact test, quantitative 
(numerical) parameters analyzed by t-student test 
Odds ratio (OR), confidence intervals (CI) and P-
values were calculated using unconditional logistic 
regression and adjusted estimate the association 
between genotypes or some other clinicopathological 
data and the risk of breast cancer. In this research, 
statistical analyses were performed using SPSS 
software ver. 21. 
 
 
Results 
 
Demographic and clinicopathological data 
 
This study was performed in 72 breast cancer 
patients and 51 healthy controls with known 
demographic and clinicopathological data in 
Mazandaran province in the north of Iran. 
Characteristics of the study population were 
compared by case-control status, as shown in Table 
1. Student's t-test showed significant relationships 
between the two groups and the mean age of controls 
(43.69 ± 13.5 years) was significantly lower (P = 
0.044) than that of breast cancer patients (48.08 ± 
10.3 years). Chi-square and Fisher exact test showed 
that Pregnancy, menopausal status, family history of 
breast cancer and education, stage of cancer and 
grade of the tumour were significantly different 
between cases and controls. However, no significant 
differences were found between them regarding BMI, 
Age at menarche, age at menopause and Age at 1 St 
pregnancy. In the case group, the frequency of level 
education is lower than diploma and difference is 
significant (p < 0.001).  
The majority of cases have a pregnancy in the 
patient group, and the difference between the two 
groups was significant (p = 0.036). Regarding the 
menopause status, the majority of cases were not at 
the menopause status (P = 0.044). In the cases 
groups, the majority of people have used LD tablets, 
and the difference between the two groups was 
significant (p = 0.043). About the stage of cancer, the 
majority of patients were in stage 2 (p < 0.001), and 
Grades of tumours were mostly reported in Grade 2 (p 
< 0.001). Regarding the agricultural occupation, few 
people were in cases group (p < 0.001). About the 
family history of cancer, the majority of patients in the 
first-degree subjects had no history of cancer in their 
family (p < 0.001). 
Regarding the distribution of genotypes, it can 
be said that distribution of genotypes in two groups in 
CYP2C8 (P = 0.11), CYP19A1 (P = 0.019), CYP1B (P 
= 0.026) Had a significant difference, and only in 
CYP1A1 (p = 0.416) is homogeneous (Table 4). 
Table 4: Genotype frequencies of genes among cases and 
controls, and risk of breast cancer 
Gene name  Genotype 
Groups Chi-square test 
Cases Controls 
Test 
statistic 
Fisher's 
exact test 
P value 
CYP2C8 
CC 62 (%86.1) 48 (%94.1) 
- 7.4 0.011* CG 0 (%0.0) 2 (%3.9) 
GG 10 (%13.9) 1 (%2.0) 
CYP19A1 
AA 3 (%4.2) 10 (%19.6) 
7.7 - 0.019* GA 42 (%58.3) 27 (%52.9) 
GG 27 (%37.5) 14 (%27/5) 
CYP1A1 
CC 56 (%77.8) 38 (%74.5) 
0.17 - 0.416 TC 16 (%22.2) 13 (%25.5) 
TT 0 (%0.0) 0 (%0.0) 
CYP1B1 
CC 38 (%52.8) 38 (%74.5) 
7.26 - 0.026* GC 20 (%27.8) 5 (%9.8) 
GG 14 (%19.4) 8 (%15.7) 
 
Also, there was no significant correlation 
between age and breast cancer risk (P = 0.13). But 
there was a significant relationship between the risk of 
cancer and menopause status, and the chance of 
having cancer is 0.466 times lower than those who did 
not have menopause status (p = 0.048). Besides, 
there was a significant relationship between the risk of 
cancer and LD Consumption, and these people have 
0.47 times higher risk of breast cancer (P = 0.043) 
(Table 5). 
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Table 5: Relation between demographic characteristic and risk 
of breast cancer 
 
Group Result 
  OR P-value CI 
Age 
< 45 31 (25%.2)  29 (22%.6) 
0.57 0.13 (0.28,1.18) 
> 45 41 (33%.3) 22 (17%.9) 
Agriculture 
NO 52 (72%.2) - 
- - - 
YES 20 (27%.8) - 
Menopause status 
NO 36 (29%.3) 36 (29%.3) 
0.466 0.048* (0.22,0.99) 
YES  15 (12%.2) 15 (12%.2) 
Family history in 
the first degree 
NO - - 
- - - 
YES - - 
OCP USE 
NO 30 (24%.4) 30 (24%.4) 
0.47 0.043* (0.23,0.98) 
YES 21 (17%.1) 21 (17%.1) 
Grade 
I, II - - 
- - - 
III - - 
Stage 
I, II - - 
- - - 
III, IV - - 
 
Regarding the relationship between the 
genotypes of each gene and the demographic 
characteristics, it can be concluded that there is no 
significant difference between the genotype and the 
demographic characteristics such as the age of the 
patients, education, pregnancy history, menopause 
status, agricultural occupation, LD consumption, stage 
of disease, grade of tumours and BMI. There was only 
a significant relationship between genotypes of 
CYP1A1 gene and education (p = 0.004), and the 
group with under diploma education had more CC 
genotype, and the group with diploma education and 
higher had the highest TC genotype. 
 
Frequency of Genotypes and Alleles 
In this case-control study, 72 breast cancer 
patients and 51 healthy controls were studied. The 
results of the experiments showed in (Table 6). The 
frequency of genotypes CYP1B1 gene among of 72 
patients was CC (52.8%), CG (27.8%) and GG 
(19.4%), and in healthy subjects was CC (74.5%) CG 
(9.8%) and GG (15.7%). The frequency of alleles in 
this genotype, allele C (66%) and G allele (34%) in 
patients and control subjects was C (80%) and G 
allele (20%). Regarding the CYP1A1 gene, the 
frequency of genotypes in patients was CC (77.8%), 
CT (22.2%) and TT (0%) and in healthy subjects were 
CC (74.5%), CT (25.5%) and TT (0%), and the 
frequency of allele C was determined in patients 
(89%) and G allele (11%) and allele C (87%) and G 
(13%) in controls have frequency. About. CYP19A1 
gene, the frequency of genotypes was determined in 
patients with GG (37.5%), GA (58.3%) and AA (4.2%), 
and in healthy subjects GG (27.5%), GA (52.9%) and 
AA (19.6%). The prevalence of alleles in patients with 
allele Cis (66%) and T (34%) and the healthy 
subjects, allele C (54%) and T (46%). Regarding the 
CYP2C8 gene, the frequency of CC (86.1%), CG (0%) 
and GG (13.9%) genotypes in patients and healthy 
subjects were CC (94.1%), CG (3.9%) and GG (2%), 
and frequency of alleles Patients were assigned C 
allele (86%) and T (14%), and in the control group, 
allele C (94%) and T (6%) were determined (Table 6). 
Regarding the relationship between the genotypes of 
each gene and breast cancer risk using a logistic 
regression model (Table 6) in two normalized and 
age-adjusted models, it was determined that in the 
CYP2C8 genotype, those who have the CG allele 
have a 7.74 degree increased risk of breast cancer 
compared to those who have the CC genotype and in 
the CYP19A1 gene of individuals with GA genotype, 
the risk of breast cancer was 6.42 compared to those 
of genotype AA (CI-%95 1.52—27.21) (Table 6), 
about the CYP1B1 gene, people with two genotypes 
of CG + GG is associated with a higher risk of breast 
cancer 2.61 times higher compared to the CC 
genotype (CI = %95 1.19-5.71) and allele G has 
protective effect in breast cancer and decreased risk 
of breast cancer (P = 0.0271) and CYP2C8 gene 
allele G decreased risk of breast cancer (P = 0.02). In 
the age-adjusted model, for the CYP2C8 gene, GG 
genotype compared to CC has an increased risk of 
breast cancer about 9.17 compared to other 
genotypes (CL = %95 1.11-75.84). Regarding 
CYP1B1, the CG + GG genotype is 2.93 times higher 
than CC genotype increased risk of breast cancer 
(CL=%95 1.31-6.57). 
Table 6: Relationship between the genotypes and breast 
cancer risk 
Genes 
name 
Genotype 
and Alleles 
groups Non-Adjusted Adjusted 
Cases (%) controls  )%(  P OR (95% CI) P OR (95% CI) 
CYP2C8 
CC 62 (86%.1) 48 (94%.1) 0.016 - 0.12 - 
CG 0 (0%.0) 2 (3%.9) 0.06 7.74 (0.95,62.5) 0.04 9.17 (1.11,75.84) 
GG 10 (13%.9) 1 (2%.0) 0.99 1.615E + 10 0.99 1.560E + 10 
CC vs GG 
+ CG 
72 (58%.53) 5 1(41%.47) 0.167 2.58 (0.67,9.89) 0.112 
3.027 
(0.77,11.88) 
C (%) 86% %96 - Ref - - 
G (%) 14% %4 P = 0.02 0.25 (0.08,0.81) - - 
CYP19A1 
AA 3 (4%.2) 10 (19%.6) 0.038 - 0.015 - 
GA 42 (58%.3) 27 (52%.9) 0.011 
6.42 
(1.52,27.21) 
0.61 6.21 (1.43,26.86) 
GG 27 (37%.5) 14 (27%.5) 0.601 1.24 (0.55,2.77) 0.066 1.24 (0.54,2.8) 
AA + GA 
vs GG 
72 (58%.53) 51 (41%.47) 0.246 1.58 (0.73,3.45) 0.263 1.57 (0.71,3.46) 
G (%) %66 %54 - Ref - - 
A (%) %34 %46 P = 0.084 1.65 (0.93,2.92) - - 
CYP1A1 
CC 56 (77%.8) 38 (74%.5) - - - - 
TC 16 (22%.2) 13 (25%.5) 0.67 
0.835 
(0.36,1.93) 
0.63 0.81 (0.34,1.9) 
TT 0 (0%.0) 0 (0%.0) - - - - 
CC vs GG 
+ CG 
72 (58%.53) 51 (41%.47) 0.67 
0.835 
(0.36,1.93) 
0.63 0.81 (0.34,1.9) 
C (%) %89 %87 - Ref - - 
T (%) %11 %13 P = 0.66 1.21 (0.51,2.84) - - 
CYP1B1 
CC 38 (52%.8) 38 (74%.5) 0.034 - 0.024 - 
GC 20 (27%.8) 5 (9%.8) 0.26 1.75 (0.66,4.65) 0.165 2.045 (0.74,5.6) 
GG 14 (19%.4) 8 (15%.7) 0.22 
0.44 
(0.118,1.62) 
0.278 0.479 (0.127,1.8) 
CC vs 
CG+GG 
72 (58%.53) 51 (41%.47) 0.016 
2.61 
(1.197,5.71) 
0.009 2.93 (1.31,6.57) 
C (%) %66 %80 - Ref - - 
G (%) %34 %20 
P = 
0.0271 
0.48 (0.25,0.92) - - 
 
The results of logistic regression model 
regarding the frequency of genotypes of each gene 
and the incidence of breast cancer indicated that there 
was a significant relationship between the frequency 
of genotypes and the risk of breast cancer only in 
CYP1B1 gene (P-value = 0.015, OR = 0.38, CI = 0.18 
0.84), and no significant results were obtained for 
other genes (Table 7). 
It’s noteworthy that CC genotype of CYP1B1 
decreases about 0.38-time risk of breast cancer in 
comparison the CG + GG genotype. In addition, for 
correlation between CC and CG + GG genotypes with 
demographic and clinical variables such as age (P-
value = 0.25), agriculture (P-value = 0.2), menopause 
(P = 0.16) (P-value = 0.29), LDL consumption (P-
value = 0.86), tumor grade (P-value = 0.83), and 
stage of cancer (P-value = 0.16), there was no 
significant relationship between two groups (Table 7). 
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Table 7: Relationship between the frequency of CYP1B1 
genotypes and the risk of breast cancer and demographic and 
clinical variables 
 
CYP1B1 Result 
CC GC + GG OR P-value CI 
Group 
Case 38 (30%.9) 34 (27.6) 
0.38 0.015* (0.18,0.84) 
Control 38 (30%.9) 13 (10%.6) 
Age 
< 45 34 (27%.6) 26 (21%.1) 
0.65 0.25 (0.32,1.36) 
> 45 42 (34%.1) 21 (17%.1) 
Agriculture 
NO 25 (34%.7) 27 (37%.5) 
0.5 0.2 (0.17,1.45) 
YES 13 (18%.1) 7 (9%.7) 
Menopause status 
NO 42 (34%.1) 32 (26%.0) 
0.58 0.16 (0.27,1.24) 
YES 34 (27%.6) 15 (12%.2) 
Family history in 
first degree 
NO 26 (36%.1) 27 (37%.5) 
0.56 0.29 (0.19,1.65) 
YES 12 (16%.7) 7 (9%.7) 
OCP USE 
NO 36 (29%.3) 23 (18%.7) 
0.94 0.86 (0.45,1.94) 
YES 40 (32%.5) 24 (19%.5) 
Grade 
I, II 32 (44%.4) 28 (38%.9) 
1.14 0.83 (0.33,3.94) 
III 6 (8%.3) 6 (8%.3) 
Stage 
I, II 22 (30%.6) 25 (34%.7) 
0.49 0.16 (0.18,1.34) 
III, IV 16 (22%.2) 9 (12%.5) 
 
 
 
Discussion 
 
Breast cancer is by far the most common 
female cancer and comprising about 21% of all new 
cancers in women. The highest age-adjusted 
incidence rate is reported for North America, is 87 per 
100 thousand women per year, while the lowest rate 
reported in China. Breast cancer follows a steeply 
increasing age gradient up to 40 years of age, after 
which the rate of increase slows down. Even though 
there are three times as many new cases diagnosed 
annually as in the late 1980s, breast cancer mortality 
has remained largely unchanged. This may at least 
partly be explained by earlier detection of the disease 
due to effective screening programs and availability of 
improved therapies. The highest annual mortality 
rates for breast cancer are reported for the UK, The 
Netherlands and Denmark, being over 25 per 100 
thousand in these countries. So far, conflicting results 
have been reported from association studies [27]. The 
aetiology of breast cancer could not be described by 
allelic variability at a single locus. Instead, the main 
burden of breast cancer in the population probably 
results from complex interactions between many 
genetic and environmental factors over time. An 
improved understanding of the interplay of xenobiotic 
exposures, endogenous physiology, and genetic 
variability at multiple loci may help to identify women 
who are at increased risk for breast cancer. The 
genetic polymorphisms that may be linked to breast 
cancer are multiple. Cumulative lifetime exposure to 
estrogen, estrogen metabolites, and other 
physiological factors, as well as environmental 
exposures, could play an important role in the 
aetiology of breast cancer in genetically predisposed 
women. Carcinogenesis, determining response to 
drugs and cell signalling. In the metabolism of 
xenobiotic (foreign chemicals), cytochrome P450s or 
monooxygenases perform an important function by 
catalysing the hydroxylation reaction [28]. CYP450 
enzymes associated with the development of breast 
cancer which involved in biosynthesis and metabolism 
of estrogens and other CYP enzymes can involve in 
the development of breast cancer risks like CYP19, 
CYP21, CYP17, CYP1A2, CYP11A1, CYP2D6, 
CYP2C19, CYP3A4/5, CYP1A1, CYP1B1, CYP2C8/9. 
In this study, distribution of CYP450 isoenzymes 
CYP1A1 (rs4646421), CYP1B1 (rs1056836), 
CYP19A1 (rs749292) and CYP2C8 (rs1058930) and 
gene polymorphisms in patients with breast cancer in 
Mazandaran province was investigated by the PCR-
RFLP method using restriction enzyme activity.  
In a study by Mandana Gheysar et al., they 
determined that through PCR-RFLP reaction, 
polymorphisms in genes involved in xenobiotic 
metabolism and estrogen biosynthesis, like CYP1A1 
(Ile462Val; rs1048943), CYP1B1 (Leu432Val; 
rs1056836) and CYP19A1 (C> T; rs10046) and they 
found an independent association of CYP1A1 (Val) 
with BC risk. CYP1B1 and CYP19A1 are not 
associated with breast cancer risk [29]. Joanna 
Trubicka et al. genotyped 597 cancer patients and 
597 controls for three CYP1B1 SNPs. They found that 
the three SNPs rs10012, rs1056827 and rs1056836 
alone did not provide any significant evidence of 
association with colorectal cancer risk. Haplotypes of 
rs1056827 and rs10012 or rs1056827 and rs1056836 
revealed an association with colorectal cancer which 
was significantly stronger in the homozygous carriers. 
Genetic variants within the CYP1B1 that are 
associated with altered function appear to influence 
susceptibility to colorectal cancer in Poland (30). In 
another study, Marc T Goodman et al., determined 
genetic variation in two CYP19A1 single-nucleotide 
polymorphisms (SNPs), rs749292 and rs727479, by 
PCR-RFLP method and association with the risk of 
ovarian cancer. Results showed that the A allele of 
rs749292 was positively associated with ovarian 
cancer risk in a codominant model for all races 
combined (AG versus AA genotype: odds ratio (OR), 
1.48 and 95% confidence interval (CI, 1.07-2.04); GG 
versus AA: OR, 1.87 (CI, 1.24-2.82); P trend = 0.002). 
Similar significant associations of the rs749292 A 
allele on the risk of ovarian cancer were found among 
Caucasian and Japanese women. No relation of the 
rs727479 SNP to ovarian cancer risk was observed 
overall, although Caucasian women carrying the 
variant A allele compared with women with a CC 
genotype had an OR of 2.91 (CI, 1.15-7.37). These 
data suggest CYP19A1 variants may influence 
susceptibility to ovarian cancer [31]. 
Jernstrometal. Investigated CYP2C8 and 
CYP2C9 polymorphisms about tumour characteristics 
and early breast cancer. In a prospective series of 652 
breast cancer patients from southern Sweden was 
genotyped for CYP2C8*3, CYP2C8*4, CYP2C9*2, 
and CYP2C9*3. Frequencies of CYP2C8/9 
polymorphisms were similar to healthy European 
populations. Significantly less node involvement 
(P¼0.002) and fewer PR   tumours (P¼0.012) were 
associated with CYP2C8*4. Median follow-up was 25 
months, and 52 breast cancer-related events were 
reported. In a multivariate model, 
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CYP2C8/9*3/*1*/*2/*1 was the only factor associated 
with increased risk for early events in 297 tamoxifen-
treated, ER-positive patients, adjusted HR 2.54 (CI = 
95% 1.11–5.79). The effect appeared to be driven by 
CYP2C8*3, adjusted HR 8.56 (95%CI 1.53-51.1). 
They found that polymorphic variants of CYP2C8/9 
may influence breast tumour characteristics and 
disease-free survival in tamoxifen-treated patients 
[32]. 
In conclusion, the results of this study indicate 
that CYP2C8 (rs1058930), CYP19A1 (rs749292) and 
CYP1B1 (rs1056836) gene polymorphisms are 
associated with breast cancer, and screening for 
these genes polymorphisms can be used to 
prognosticate disease, prevent disease progression, 
and to use appropriate therapeutic. 
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